# PurpleLab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/purplelab

- Industry: Software
- Headquarters: US
- Website: www.purplelab.com
- Total disclosed funding: $43M
- Latest round: Series B (Jul 27, 2022)
- Investors on record: 2

## About

PurpleLab, Inc. is a healthcare analytics company that provides innovative solutions through its HealthNexus® platform, designed to empower life sciences firms and healthcare providers with actionable insights from real-world data.Founded in 2016 in the US, PurpleLab, Inc. specializes in healthcare analytics. The company has secured a total amount raised of USD 40.00 mn through its Series B funding round, led by Primus Capital in July 2022, with participation from Edison Partners. Mark Brosso, the CEO and founder, has a history of entrepreneurship, contributing to the company’s strategic vision and growth.PurpleLab® offers a comprehensive suite of healthcare analytics solutions primarily through their flagship platform, HealthNexus®. This no-code platform enables life sciences companies, healthcare providers, and payers to analyze real-world data (RWD) effectively, providing insights into patient populations, market opportunities, and healthcare practitioner (HCP) behaviors. The platform facilitates the identification, characterization, and quantification of various healthcare entities, allowing clients to optimize their sales and marketing strategies through targeted outreach. HealthNexus® supports multiple use cases, including campaign performance tracking, therapy adoption analysis, and competitive market share insights, serving clients such as pharmaceutical companies, medical device manufacturers, healthcare agencies, and media companies primarily in the United States, with a growing presence in international markets.PurpleLab® generates revenue through a subscription-based model for its HealthNexus® platform, which allows clients to access and utilize their analytics tools. Clients engage with the platform under different pricing tiers based on their needs and the scale of data access required, which may include options for small practices to large healthcare organizations. The structure of transactions typically involves direct-to-business agreements, whereby clients subscribe to the service for a specific term, ensuring ongoing access to analytics tools and data insights. This model supports a continuous revenue stream while enabling clients to leverage PurpleLab’s® capabilities for pre-campaign planning and post-campaign assessments, thereby enhancing their decision-making processes in the healthcare market.In July 2022, PurpleLab, Inc. raised USD 40.00 mn in Series B funding led by Primus Capital, which will be utilized to continue the company’s growth trajectory, accelerate investments in new data assets, and develop product and human capital. The company plans to expand into new geographic markets, targeting international regions to enhance its global footprint. Upcoming product launches are being designed to further enhance the capabilities of the HealthNexus® platform, although specific release dates are not yet disclosed.

## Funding rounds

- Series B, Jul 27, 2022, $40M — Edison Partners, Primus
- Series A, Jul 1, 2019, $3M — Edison Partners

## Investors

- Edison Partners (https://capitalatlas.ai/funds/edison-partners) — Series A, Series B
- Primus (https://capitalatlas.ai/funds/primus) — Series B